Amphastar Pharmaceuticals, Inc. disclosed two related party agreements effective March 3, 2026: a 5-year Supply Agreement with Nanjing Letop Biotechnology Co., Ltd. for chemical intermediates via its subsidiary Amphastar Nanjing Pharmaceuticals, Inc., and an amendment to a Contract Research Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. changing product candidate from AMP-107 to AMP-105 and increasing total cost by approximately $0.6 million. Both were approved by the Audit Committee and deemed non-material to financial condition or results of operations.
Key takeaways
Supply Agreement effective March 3, 2026 between Amphastar Nanjing Pharmaceuticals, Inc. and Nanjing Letop Biotechnology Co., Ltd. for chemical intermediates, 5-year term, payments in Chinese yuan.
No minimum purchase obligation under Supply Agreement.
Contract Research Amendment effective March 3, 2026 changes product to AMP-105 from AMP-107, adds ~$0.6 million cost.
Letop majority owned by Henry Zhang, immediate family member of CEO Dr. Jack Zhang and Chairman Dr. Mary Luo.
Hanxin majority owned by Dr. Jack Zhang, Dr. Mary Luo, and family; Henry Zhang is general manager and chairman.
Both transactions approved by Audit Committee; company states neither is material.